Melbourne biotech group Dia-B expects to begin clinical trials of its ISF402 anti-diabetes compound in the last quarter of 2006 after initial trials on animals proved that the compound is effective in lowering blood glucose levels.
Initial animal sighting studies showed no toxicity, and Dia-B is confident that ISF402 will be ready for human trials in the final quarter.
Recently completed animal studies on rabbits have shown that ISF402 works when delivered orally. This is in addition to prior work that confirmed the success of lowering blood glucose when ISF402 was given orally to rats. The effective dose in rabbits was 4-fold lower than in rats.
ISF402 as an oral drug can enhance insulin action to reduce glucose in the blood stream of the body, and to potentially benefit type 2 diabetes sufferers world wide, said Dia-B Chairman Dr Michael Wooldridge.